- China Yuchai International Limited (NYSE:CYD) unit GYMCL’s subsidiary YMMC has formed a new joint venture, Suzhou Yuxing Automobile Technology Co., Ltd.
- The JV will enhance the nationwide engine services and emergency services for all vehicles powered by Yuchai engines in China. The total registered capital for Suzhou Yuxing is RMB 5 million, pro-rated among the equity owners by their respective interest.
- YMMC has a 30% equity interest in the JV. Xingwei Automobile Technology (Wuxi) Co., Ltd. owns a 25% equity interest, Tianjin Zhuoyu Automobile Technology Partnership has an 8% equity interest, and Fujian Zhongchuang Chelian Network Technology Co., Ltd., has a 12% equity interest.
- Tianjin Zhongding Chuangxing Automobile Technology Partnership, incorporated by YMMC’s distributors, owns a 25% equity interest in the JV.
- Price Action: CYD shares are trading lower by 0.19% at $10.79 on the last check Tuesday.
Fate Therapeutics Q4 EPS $(0.72) Misses $(0.67) Estimate, Sales $17.10M Beat $10.73M Estimate
Fate Therapeutics (NASDAQ:FATE) reported quarterly losses of $(0.72) per share which missed the analyst consensus estimate of $(0.67) by 7.46 percent. This is a 18.03 percent decrease over losses of $(0.61) per share
